Evidence map›Paper›PMID 41180369›Full record

ReviewAPL bioengineering2025

Synergy between photonics and biological approaches-A review of combination therapies for cancer theranostics.

Jacob P Adams, Luke Pauli, Lin Wang, Trisha Valerio, Coline Furrer, Min Li, Naoko Takebe, Joanne Tuohy, Wei R Chen

Abstract readReview
In one paragraph

Review in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jacob P AdamsStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma 73019, USA.ORCID https://orcid.org/0009-0004-6277-5159
Luke PauliStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma 73019, USA.ORCID https://orcid.org/0009-0006-5541-9417
Lin WangStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma 73019, USA.ORCID https://orcid.org/0000-0003-4636-8225
Trisha ValerioStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma 73019, USA.
Coline FurrerStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma 73019, USA.ORCID https://orcid.org/0000-0002-8822-3887
Joanne TuohyVA-MD College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia 24061, USA.ORCID https://orcid.org/0000-0003-1516-3841
Wei R ChenStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma 73019, USA.ORCID https://orcid.org/0000-0002-7133-5794

Funding

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumorsR01CA269897 · NCI · UNIVERSITY OF OKLAHOMA · PI Wei R. Chen, MIN LI · 2022 to 2026
$2.5M
Mechanistic study on synergistic photo-immunological effects of laser immunotherapy for metastatic cancersR01CA205348 · NCI · UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · 2017 to 2021
$1.5M
NCI NIH HHS R01 CA205348NCI NIH HHS R01 CA269897
6 · The paper itself

Abstract

Cancer therapies have evolved considerably over the past several decades. Physical interactions, particularly through phototherapy as a new class of treatment modality, have become widely used. Phototherapy utilizes light to combat cancer by generating heat (photothermal therapy), reactive oxygen species (photodynamic therapy), or photochemical internalization, to kill targeted cells. While these therapies have shown promise in pre-clinical studies, they have demonstrated limitations in clinical cancer treatment. Primarily, while phototherapies excel in eliminating primary tumors, they often fail to provide systemic effects, particularly when treating metastatic cancers, in addition to certain undesirable side effects. Phototherapy has been combined with immunotherapy, nanomedicine, and other cancer therapies to overcome specific weaknesses and enhance the therapeutic benefits of individual treatments. These combinations often involve nanomaterials to deliver adjuncts for phototherapy to the tumor site, immune stimulants/adjuvants to enhance the immune response, and immune checkpoint inhibitors to counter immune suppression. Phototherapies may also be combined with specific photonics-related principles to enable simultaneous diagnostic and therapeutic effects, known as theranostics. Herein, we review current approaches to modern cancer therapies, such as nanotechnology-based therapies, immunotherapies, and especially phototherapy, and the combination of these therapies with diagnostic techniques in combating cancer.

Identifiers

PMID41180369
PMCPMC12575004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.